Drugs / Nanatinostat
Nanatinostat
also known as
CHR-3396 · CHR-3996 · Hdac inhibitor chr-3996 · Nanatinostat (free base) · Nanatinostat mesylate · VRx-3996
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06302140 | Feb 2024 → Jan 2025 | — | Viracta Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05166577 | Oct 2021 → Oct 2024 | Epstein-Barr virus-associated gastric carcinoma, Epstein-Barr virus-associated mesenchymal tumor, nasopharyngeal carcinoma | Viracta Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT00697879 | Feb 2008 → Nov 2010 | cancer | Chroma Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03397706 | Mar 2018 → Apr 2023 | Epstein-Barr virus-associated lymphoproliferative disorder, lymphoproliferative syndrome | Viracta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05011058 | May 2021 → Dec 2024 | Hodgkins lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified, post-transplant lymphoproliferative disease | Viracta Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nanatinostat | “second-generation histone deacetylase (HDAC) inhibitor, nanatinostat (previously referred to as either VRx-3996 or CHR-3396)” NCT03397706 ↗ |
| Known as | CHR-3396 | “second-generation histone deacetylase (HDAC) inhibitor, nanatinostat (previously referred to as either VRx-3996 or CHR-3396)” NCT03397706 ↗ |
| Known as | CHR-3996 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00697879 ↗ |
| Known as | Hdac inhibitor chr-3996 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1801250 ↗ |
| Known as | Nanatinostat (free base) | “Treatment A: a single, oral dose of nanatinostat (free base) tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.” NCT06302140 ↗ |
| Known as | Nanatinostat mesylate | “Treatment B: a single, oral dose of nanatinostat mesylate tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.” NCT06302140 ↗ |
| Known as | VRx-3996 | “second-generation histone deacetylase (HDAC) inhibitor, nanatinostat (previously referred to as either VRx-3996 or CHR-3396)” NCT03397706 ↗ |
| Action | Inhibit | “Nanatinostat is a class-I selective oral histone deacetylase inhibitor” PMID 37530631 ↗ Oct 2023 |
| Modality | Small molecule | — CHEMBL1801250 ↗ |
| Route | Oral | “Once daily oral ingestion of capsules (5, 10, 20 or 40 mg), dose depending on cohort, treatment cycle of 28 days” NCT00697879 ↗ |